News
DRAP- HKBMIA Workshop
Workshop On Chemistry, Manufacturing, and Control (CMC)
On June 4–5, 2025, the MSc Program in Drug Regulatory Affairs and Policy (DRAP) program of The Hong Kong University of Science and Technology (HKUST), in collaboration with the Hong Kong Bio-Med Innotech Association (HKBMIA), have successfully hosted a CMC training workshop. The theme of the training was Chemistry, Manufacturing, and Controls (CMC). Delivered through a collaborative effort by four expert instructors.
Seminar on 12 May 2025 Division of Life Science
Introduction to GMP Inspection
The workshop featured an engaging presentation by Dr. Zhigang Sun, Group Senior Vice President at Luye Pharma Group and Adjunct Professor at the Hong Kong University of Science and Technology. In his keynote address, Dr. Sun—who oversees global drug product development, quality (GLP/GCP/GMP compliance), and pharmacovigilance (GVP compliance) at Luye Pharma—shared valuable insights with attendees.
Seminar on 2 Apr 2025 Division of Life Science
The Digital Leap: Exploring AI In Drug and Medical Device Innovations
by Dr. Mann Fung, Adjunct Professor, Clinical Research Institute, Peking University, Beijing, China.
This seminar delves into AI’s multifaceted contributions, encompassing its commercial viability, historical evolution, practical applications, regulatory landscape, and future trajectories.
Seminar on 10 Feb 2025 Division of Life Science
The Global Biotech Investment Landscape: Insights from the US NIH & FDA, and Implications for Hong Kong’s Prospects
by Dr. Jing Bao, Adjunct Professor, Division of Life Sciences, HKUST, Partner, Shanghai Healthcare Capital.
The biotech industry is undergoing rapid transformation, driven by scientific breakthroughs, regulatory shifts, and evolving investment trends. At the same time, it faces a challenging investment “winter,” marked by tighter funding, increased scrutiny, and market volatility.
HKUST-NEU Webinar
Recent Advances in Global Cell Gene Therapy Development
The impact of cell gene therapy has grown significantly in recent years for many disease treatments and patient cares. It is important to understand its origin, current practices, and future growth globally as the technology is being applied worldwide.
Seminar on 25 Oct 2024 Division of Life Science
The Miracle of Science: Lessons Learned from the COVID Vaccine Development
by Dr. Jing Bao, Adjunct Professor, MSc DRAP, Division of Life Science, HKUST.
In this talk, Dr. Bao, a physician-scientist with 16 years of experience overseeing U.S. NIH-sponsored scientific projects and clinical trials, delves into the unprecedented global collaboration among scientists, governments, and industry that enabled the rapid identification, testing, clinical trials, regulatory approval, and distribution of these life-saving vaccines without compromising safety.
Orientation event
MSc DRAP Orientation Event - 4 September 2024
Orientation event for the MSc in Drug Regulatory Affairs and Policy (DRAP) program on 4 September 2024 from 5:30 PM to 7:00 PM (Room 5464, Division of Life Science, Lift 25-26). This is a wonderful opportunity for all full-time and part-time Fall 2024-25 MSc DRAP students to meet each other, as well as engage with professors and capstone advisors.
Seminar on 23 Sep 2024 Division of Life Science
Biomanufacturing: A case study from facility design to 1st batch of GMP manufacturing, a successful case from 0 to 1 transition
by Prof. Alan Wong, Adjunct Assistant Professor, MSc DRAP, Division of Life Science, HKUST.
It is critical to do the right things from facility design, built out, equipment procurement, commissioning, qualification, facility release to GMP manufacturing in order to avoid unexpected events occurring impacting delivery of the finished project on time.
Seminar on 9 Aug 2024 Division of Life Science
Making New Drugs the Hard Way
by Dr. Dennis Liotta, PhD, DSc, Department of Chemistry, Emory University, Atlanta.
This presentation commences with an overview of Dr. Liotta's remarkable achievements in the field of antiviral research. The initial segment will delve into the success stories of three groundbreaking drugs developed by Emory and its spinoffs, addressing critical public health emergencies such as the HIV/AIDS epidemic, the HCV challenge, and the COVID-19 pandemic.